JP2005523281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523281A5 JP2005523281A5 JP2003569193A JP2003569193A JP2005523281A5 JP 2005523281 A5 JP2005523281 A5 JP 2005523281A5 JP 2003569193 A JP2003569193 A JP 2003569193A JP 2003569193 A JP2003569193 A JP 2003569193A JP 2005523281 A5 JP2005523281 A5 JP 2005523281A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- alpha
- pharmaceutically acceptable
- delta ligand
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010007710 Cartilage injury Diseases 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- -1 1-aminomethyl-cyclohexylmethyl Chemical group 0.000 claims 1
- UVUQVKDHNYUOJX-UHFFFAOYSA-N 2h-oxadiazol-5-one;hydrochloride Chemical compound Cl.O=C1C=NNO1 UVUQVKDHNYUOJX-UHFFFAOYSA-N 0.000 claims 1
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35929502P | 2002-02-22 | 2002-02-22 | |
| US40436502P | 2002-08-19 | 2002-08-19 | |
| PCT/IB2003/000534 WO2003070237A1 (en) | 2002-02-22 | 2003-02-12 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523281A JP2005523281A (ja) | 2005-08-04 |
| JP2005523281A5 true JP2005523281A5 (https=) | 2006-03-30 |
Family
ID=27760521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569193A Abandoned JP2005523281A (ja) | 2002-02-22 | 2003-02-12 | アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20030199567A1 (https=) |
| EP (1) | EP1480639A1 (https=) |
| JP (1) | JP2005523281A (https=) |
| KR (1) | KR20040085216A (https=) |
| CN (1) | CN1635887A (https=) |
| AR (1) | AR038531A1 (https=) |
| AU (1) | AU2003246864A1 (https=) |
| BR (1) | BR0307906A (https=) |
| CA (1) | CA2476438A1 (https=) |
| CO (1) | CO5611109A2 (https=) |
| HN (1) | HN2003000071A (https=) |
| IL (1) | IL162932A0 (https=) |
| MX (1) | MXPA04008175A (https=) |
| NO (1) | NO20043947L (https=) |
| PA (1) | PA8567201A1 (https=) |
| PE (1) | PE20031052A1 (https=) |
| PL (1) | PL372210A1 (https=) |
| RU (1) | RU2286151C2 (https=) |
| TW (1) | TW200303214A (https=) |
| UY (1) | UY27675A1 (https=) |
| WO (1) | WO2003070237A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004054560A1 (en) * | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
| WO2004084880A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
| WO2004084881A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
| DE602004003172T2 (de) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
| US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| NZ545494A (en) * | 2003-09-12 | 2009-10-30 | Pfizer | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| WO2005041976A2 (en) * | 2003-10-23 | 2005-05-12 | Medtronic, Inc. | Injectable gabapentin compositions |
| AR060404A1 (es) * | 2006-04-11 | 2008-06-11 | Novartis Ag | Compuestos organicos utiles como inhibidores de dipeptidil-peptidasa iv |
| US20130012485A1 (en) * | 2006-12-22 | 2013-01-10 | Baeschlin Daniel Kaspar | Organic compounds |
| CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
| SI2735338T1 (sl) * | 2008-09-05 | 2019-04-30 | Grunenthal Gmbh | Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina |
| KR102631399B1 (ko) | 2018-03-30 | 2024-02-01 | 씨지인바이츠 주식회사 | 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물 |
| JP2023548380A (ja) * | 2020-10-28 | 2023-11-16 | トレモー・ファーマシューティカルズ・インコーポレイテッド | 非水溶性ｃｏｘ－２阻害の水性製剤 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234929A (en) * | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5420270A (en) * | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5352638A (en) * | 1994-02-22 | 1994-10-04 | Corning Incorporated | Nickel aluminosilicate glass-ceramics |
| RU2168982C2 (ru) * | 1994-07-27 | 2001-06-20 | Варнер-Ламберт Компани | Способ лечения состояния страха или лечения и/или предупреждения состояния паники, очищенный белок, способный связывать габапентин, и фармацевтическая композиция, обладающая успокоительным, противопаническим и противосудорожным действием |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| WO1999008670A1 (en) * | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| WO1999012537A1 (en) * | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| CA2304967C (en) * | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| US6451857B1 (en) * | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
-
2003
- 2003-02-12 RU RU2004125609/15A patent/RU2286151C2/ru not_active IP Right Cessation
- 2003-02-12 EP EP03742460A patent/EP1480639A1/en not_active Withdrawn
- 2003-02-12 MX MXPA04008175A patent/MXPA04008175A/es unknown
- 2003-02-12 JP JP2003569193A patent/JP2005523281A/ja not_active Abandoned
- 2003-02-12 CN CNA038043564A patent/CN1635887A/zh active Pending
- 2003-02-12 WO PCT/IB2003/000534 patent/WO2003070237A1/en not_active Ceased
- 2003-02-12 PL PL03372210A patent/PL372210A1/xx not_active Application Discontinuation
- 2003-02-12 CA CA002476438A patent/CA2476438A1/en not_active Abandoned
- 2003-02-12 BR BR0307906-6A patent/BR0307906A/pt not_active IP Right Cessation
- 2003-02-12 AU AU2003246864A patent/AU2003246864A1/en not_active Abandoned
- 2003-02-12 KR KR10-2004-7013032A patent/KR20040085216A/ko not_active Ceased
- 2003-02-12 IL IL16293203A patent/IL162932A0/xx unknown
- 2003-02-14 US US10/366,798 patent/US20030199567A1/en not_active Abandoned
- 2003-02-17 PE PE2003000166A patent/PE20031052A1/es not_active Application Discontinuation
- 2003-02-19 UY UY27675A patent/UY27675A1/es not_active Application Discontinuation
- 2003-02-20 AR ARP030100547A patent/AR038531A1/es unknown
- 2003-02-21 TW TW092103596A patent/TW200303214A/zh unknown
- 2003-02-21 PA PA20038567201A patent/PA8567201A1/es unknown
- 2003-02-21 HN HN2003000071A patent/HN2003000071A/es unknown
-
2004
- 2004-08-13 CO CO04079024A patent/CO5611109A2/es not_active Application Discontinuation
- 2004-09-21 NO NO20043947A patent/NO20043947L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523281A5 (https=) | ||
| RU2379295C2 (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| JP2005523922A5 (https=) | ||
| RU2011129222A (ru) | Гемифумаратная соль 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил] азетидин-3-карбоновой кислоты | |
| EP2251327A3 (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
| JP2008543854A5 (https=) | ||
| RU2004125609A (ru) | Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2 | |
| RU2010145459A (ru) | Ингибиторы активности протеинтирозинкиназы | |
| JP2007534702A5 (https=) | ||
| JP2009504763A5 (https=) | ||
| RU2008112683A (ru) | Ингибиторы fap | |
| WO2006098918B1 (en) | Substituted gamma lactams as therapeutic agents | |
| EA200870384A1 (ru) | 3,7-диамино-10h-фенотиазиновые соли и их применение | |
| JP2009525302A5 (https=) | ||
| CA2158352A1 (en) | Hydroxamic acid derivatives as metalloproteinase inhibitors | |
| RU2011129229A (ru) | Новые соли | |
| EP2228064A3 (en) | Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist | |
| JP2003503449A5 (https=) | ||
| JP2013502461A5 (https=) | ||
| JP2009520695A5 (https=) | ||
| MXPA05006333A (es) | Metodo de tratamiento. | |
| RU2003134629A (ru) | Соединения цефема | |
| RU2004101229A (ru) | Дейтерированные n-и альфа-замещенные аминоалкилэфиры дифенилакоксиуксуной кислоты, а также лекарственные средства, содержащие эти соединения | |
| JP2005521664A5 (https=) | ||
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств |